AlphAIalphai — Financial news for AI agents
finanznachrichten.deAUG 127 min read$PYPD

PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Ltd. (Nasdaq: PYPD) said the FDA accepted its D-PLEX100 NDA for priority review for preventing surgical site infections in abdominal colorectal surgery, with a PDUFA goal date of Nov. 28, 2026. PolyPid entered an exclusive U.S. and Canada commercialization partnership with Azurity, receiving $30 million upfront and near-term milestones, plus tiered mid-teen to mid-twenties royalties. Q2 2026 net loss was $7.8M.

Original reporting
finanznachrichten.de
Published Aug 12, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$PYPD
Bullish
high confidence
Mentioned
$PYPD
Relevance
9/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$PYPDBullishHigh
01

Why it matters

FDA acceptance with Priority Review and a defined PDUFA date compresses the regulatory uncertainty window. The Azurity partnership adds confirmed upfront cash and a large milestone/royalty framework, reducing near-term financing risk while the company prepares for potential early-2027 US launch.

02

Market read

This is a catalyst-heavy update for PYPD: FDA acceptance with Priority Review, a specific PDUFA date, and a commercialization partnership that confirms near-term cash and expands upside via milestones and royalties.

03

What to watch

The article does not provide detailed safety outcomes or manufacturing readiness specifics; commercialization success depends on Azurity execution and payer/market adoption, not just FDA review progress.

Relevance 9/10Novelty 9/10Timing: today’s corporate update, with PDUFA goal date set for Nov. 28, 2026

Background

PolyPid is advancing D-PLEX100, a drug candidate for preventing surgical site infections in abdominal colorectal surgery, using its Kynatrix technology platform.

Company-level read

Ticker impact

$PYPDBullishHigh confidence
Context

PolyPid reports FDA accepted its D-PLEX100 NDA with Priority Review and sets a PDUFA goal date of Nov. 28, 2026.

Expected impact

Bullish bias into the Nov. 28, 2026 PDUFA window, with volatility around FDA review updates and Azurity commercialization milestones.

Evidence & confidence

The article discloses a fresh FDA acceptance event, Priority Review status, and a specific PDUFA date, plus a confirmed $30M upfront milestone and a large potential milestone/royalty structure tied to commercialization.

Market effects

Sector

Reinforces investor appetite for surgical infection prevention assets and can lift sentiment for small-cap specialty biopharma with near-term FDA catalysts.

Regional

Limited direct regional spillover beyond US biotech risk appetite.

Global

US FDA milestone and potential EU MAA timing can influence global peers’ expectations for similar anti-infection or surgical prophylaxis programs.

Counterpoint

What could challenge this read

Priority Review acceptance does not guarantee approval; investors may be overpaying for timeline de-risking while efficacy, safety, and label negotiations remain ahead.

Key entities

  • company
    PolyPid Ltd.

    Nasdaq-listed biopharmaceutical company advancing D-PLEX100 and reporting FDA NDA acceptance plus financial results.

  • drug_candidate
    D-PLEX100

    PolyPid’s NDA-stage therapy for prevention of surgical site infections in abdominal colorectal surgery.

  • regulator
    FDA

    Accepted the D-PLEX100 NDA and granted Priority Review with a Nov. 28, 2026 PDUFA goal date.

  • partner
    Azurity Pharmaceuticals

    Commercialization partner for US and Canada, providing $30M upfront and potential additional milestones and royalties.

  • regulator
    EMA

    Planned third-quarter 2026 MAA submission for D-PLEX100 under the centralized procedure.

Read at source← All news

Related articles

JUL 29
$PYPDMedAI 8/10

PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100

PolyPid (Nasdaq: PYPD) said the FDA accepted its NDA for D-PLEX100 to prevent surgical site infections in abdominal colorectal surgery and granted Priority Review. The PDUFA target action date is Nov. 28, 2026. FDA found no filing review issues. Acceptance triggers a $15 million milestone from Azurity, completing $30 million in upfront and near-term milestones.

finanznachrichten.de2 min
JUL 24
$PYPDMedAI 8/10

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD) said it signed an exclusive commercialization deal with Azurity Pharmaceuticals for D-PLEX100 to prevent abdominal surgical site infections in the U.S. and Canada. PolyPid gets $15M upfront, $15M on FDA NDA acceptance, and up to $300M in milestones. Deal follows Phase 3 SHIELD II results; U.S. launch targeted Q1 2027. Analysts at Roth and H.C. Wainwright set Buy ratings and $9 and $13 targets.

streetwisereports.com7 min
AUG 12
$BAMed

Home | Carlsbad Current Argus

The FAA said Boeing submitted an action plan to address “systemic quality control issues” after an Alaska Airlines door plug failure in January. The plan includes strengthening safety management, improving employee safety reporting, simplifying procedures, enhancing supplier oversight, increasing internal audits, and boosting training and communication.

currentargus.com2 min
AUG 12
$PCGMed

Newsom makes last-minute push to help California utilities facing wildfire bills

California Governor Gavin Newsom is urging lawmakers to pass bills to reduce investor-owned utilities’ wildfire-related liability and the profit impact of payouts. The proposal faces opposition from insurers and wildfire survivors’ attorneys, while PG&E, Southern California Edison, and San Diego Gas & Electric say they may act if changes are not approved. The state’s wildfire fund is expected to be depleted as claims are tallied.

paloaltoonline.com7 min
AUG 12
$COHRMed

How optical interconnects and silicon photonics emerged as AI's next hot commodity — looming US-China summit puts photonics into the crosshairs

The FCC is drafting a rule under the Secure Networks Act to block import authorization for new Chinese optical transceiver models, aiming to publish before end-2026, according to Reuters. Shares of China’s Zhongji Innolight, Eoptolink and TFC Optical fell in early Shenzhen trading, while Coherent and Lumentum rose. Nvidia reportedly committed $4B to Coherent and Lumentum; Marvell agreed $3.25B upfront for Celestial AI.

tomshardware.com7 min
AUG 12
$UBERMed

New Colorado rideshare safety provisions take effect

Colorado’s new Rideshare Safety and Accountability Act (HB 1424) takes effect Wednesday, requiring Uber and Lyft to investigate driver complaints within seven business days or face penalties. The law also targets account impersonation and sets further rules by Jan 2027 and June 2028. Supporters cite safety concerns and prior lawsuits; Uber and Lyft say they already have processes.

coloradosun.com6 min